摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-allyl-4-nitroanisole | 562080-95-9

中文名称
——
中文别名
——
英文名称
2-allyl-4-nitroanisole
英文别名
2-allyl-1-methoxy-4-nitrobenzene;1-allyl-2-methoxy-5-nitrobenzene;1-methoxy-4-nitro-2-prop-2-enylbenzene
2-allyl-4-nitroanisole化学式
CAS
562080-95-9
化学式
C10H11NO3
mdl
MFCD27925533
分子量
193.202
InChiKey
GSGTVCLGXRUFIK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    55
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-allyl-4-nitroanisole 在 palladium on activated charcoal 、 氢气 作用下, 生成 4-Methoxy-3-propylaniline
    参考文献:
    名称:
    芳基三烷基铵盐催化还原成芳基硅烷和芳烃†
    摘要:
    报道了一种使用镍催化将芳基铵盐还原为芳烃或芳基硅烷的新方法。该方法基于使用的N杂环卡宾(NHC)配体显示出出色的配体控制选择性。在非极性溶剂中使用较大的NHC会生成芳基硅烷,而在极性溶剂中使用较小的NHC会促进还原为芳烃。可以从简单的苯胺结构单元中获得几类芳基硅烷,包括可用于交叉偶联,氧化和卤化的那些。反应条件温和,可耐受官能团,可有效接触各种苯衍生物。
    DOI:
    10.1039/c9sc01083a
  • 作为产物:
    描述:
    参考文献:
    名称:
    Ortho- and Para-Substituted Hoveyda−Grubbs Carbenes. An Improved Synthesis of Highly Efficient Metathesis Initiators
    摘要:
    A novel highly efficient and general route to various 3- and 5-substituted 2-alkoxystyrenes, required for the preparation of Hoveyda-Grubbs catalysts, is described.
    DOI:
    10.1021/jo049222w
点击查看最新优质反应信息

文献信息

  • Indole derivative having piperidine ring
    申请人:Suzuki Yuichi
    公开号:US20050256103A1
    公开(公告)日:2005-11-17
    The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R 1 and R 2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R 3 represents a hydrogen atom or the like; and R 6 represents a hydrogen atom or the like. It is an object of the present invention to discover an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage, which has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor.
    本发明涉及以下公式所代表的化合物,其药学上可接受的盐,或其作为药物的用途: 其中R1和R2是相邻的取代基,与它们各自连接的两个碳原子一起形成一个5-至7-成员非芳香碳环基或类似物,该基可能被1至4个取代基所取代,所述取代基选自(1)氧代基,(2)羟基等;R3代表氢原子或类似物;R6代表氢原子或类似物。 本发明的目的是发现一种用于治疗或预防下尿道症状,特别是涉及尿液储存的症状的药剂,该药剂具有优越的结合力与5-HT1A受体结合并对该受体具有拮抗作用。
  • Indole Derivative Having Piperidine Ring
    申请人:Suzuki Yuichi
    公开号:US20070219179A1
    公开(公告)日:2007-09-20
    The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R 1 and R 2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R 3 represents a hydrogen atom or the like; and R 6 represents a hydrogen atom or the like. This compound has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor, and is useful as an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage.
    本发明涉及一种化合物,其表示为以下公式,其药理学上可接受的盐或其用途作为药物:其中R1和R2是相邻的取代基,并与它们附着的两个碳原子一起形成一个5-至7-成员的非芳香族碳环基团或类似物,该基团可以被1至4个取代基所取代,所述取代基包括(1)氧代基、(2)羟基等;R3表示氢原子或类似物;R6表示氢原子或类似物。该化合物具有优越的与5-HT1A受体结合的强度和对受体的拮抗作用,并可用作治疗或预防下尿路症状,特别是涉及尿液储存的症状的药剂。
  • 1-(Piperidin-4- Yl)-1H-Indole Derivatives
    申请人:Suzuki Yuichi
    公开号:US20080119518A1
    公开(公告)日:2008-05-22
    The present invention provides a compound represented by the formula (1) or a pharmacologically acceptable salt thereof, or a hydrate thereof (provided that a compound in which all of R4a, R4b, and R4c are hydrogen atoms is excluded.): [wherein R1 represents a hydrogen atom, R2 represents a hydrogen atom, R3 represents the formula: wherein R4a, R4b, and R4c are the same as or different from each other and each represents a hydrogen atom, a C 1-6 alkyl group or a C 1-6 alkoxy group, etc.]
    本发明提供了一种由式(1)表示的化合物或其药学上可接受的盐,或其水合物(前提是排除所有R4a、R4b和R4c均为氢原子的化合物):[其中R1表示氢原子,R2表示氢原子,R3表示式:其中R4a、R4b和R4c相同或不同,且每个表示氢原子、C1-6烷基或C1-6烷氧基等。]
  • INDOLE DERIVATIVES HAVING PIPERIDINE RINGS
    申请人:Eisai R&D Management Co., Ltd.
    公开号:EP1757599A1
    公开(公告)日:2007-02-28
    The present invention relates to a compound represented by the following formula, a pharmacologically acceptable salt thereof, or a use thereof as a pharmaceutical: wherein R1 and R2 are substituents adjacent to each other, and together with two carbon atoms to each of which they attach, form a 5- to 7-membered non-aromatic carbocyclic group or the like, which may be substituted by 1 to 4 substituents selected from (1) an oxo group, (2) a hydroxyl group, and the like; R3 represents a hydrogen atom or the like; and R6 represents a hydrogen atom or the like. This compound has a superior strength of binding to a 5-HT1A receptor and an antagonism to the receptor, and is useful as an agent for treating or preventing lower urinary tract symptoms, and particularly symptoms regarding urinary storage.
    本发明涉及下式所代表的化合物、其药理学上可接受的盐,或其作为药物的用途: 其中 R1 和 R2 是彼此相邻的取代基,并与它们各自连接的两个碳原子一起构成 5 至 7 元的非芳香族碳环基团或类似基团,该基团可被 1 至 4 个选自(1)氧代基团、(2)羟基和类似基团的取代基取代;R3 代表氢原子或类似基团;R6 代表氢原子或类似基团。该化合物与 5-HT1A 受体的结合强度较高,对受体有拮抗作用,可作为治疗或预防下尿路症状,特别是储尿症状的药物。
  • 1-(PIPERIDIN-4-YL)-1H-INDOLE DERIVATIVE
    申请人:Eisai R&D Management Co., Ltd.
    公开号:EP1847535A1
    公开(公告)日:2007-10-24
    The present invention provides a compound represented by the formula (1) or a pharmacologically acceptable salt thereof, or a hydrate thereof (provided that a compound in which all of R4a, R4b, and R4c are hydrogen atoms is excluded.): [wherein R1 represents a hydrogen atom, R2 represents a hydrogen atom, R3 represents the formula: wherein R4a, R4b, and R4c are the same as or different from each other and each represents a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group, etc.]
    本发明提供了一种由式(1)表示的化合物或其药理学上可接受的盐,或其水合物(但不包括R4a、R4b和R4c全部为氢原子的化合物): [其中 R1 代表氢原子,R2 代表氢原子,R3 代表式(1): 其中 R4a、R4b 和 R4c 彼此相同或不同,且各自代表氢原子、C1-6 烷基或 C1-6 烷氧基等]。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐